Self-Assessment Study Program SASP (2017)

The SASP is the AUA’s most popular study tool for exam preparation! To meet your learning preference, the SASP is available in three convenient formats—booklet, online, and the innovative Q-Stream format which sends questions directly to your smartphone, computer or tablet. Pricing will be displayed upon format selection. Offering up to 20 AMA PRA Category 1 Credits™.

For 40 years, the AUA's Self-Assessment Study Program (SASP) has been a leading educational resource for urologists-in-training and practicing urologists. Developed each year, the SASP is a 150-question, multiple-choice practice examination that addresses the core curriculum of medical knowledge and latest advances in patient care. The SASP may be taken open or closed book, and provides correct answers with detailed answer rationales, and scientific references.

Why is the SASP the AUA's most popular study tool for exam preparation?

Constructed in the same style as the AUA and ABU's multiple-choice examinations—and offered in three convenient formats to meet your unique study preference—SASP is the AUA's most popular study tool for exam preparation. SASP provides participants their scores, the average scores of their peers, and access to answer commentary and scientific references, allowing participants to evaluate their strengths and weaknesses in various clinical areas and enrich their learning experience. Also, it is important to note that 20 – 30 percent of the content of the ABU Recertification Examination comes directly from SASP!

Offering up to 20 AMA PRA Category 1 Credits™, the SASP also helps to fulfill the CME requirements mandated by the ABU Maintenance of Certification (MOC)© process.


Target Audience

  • Urologists
  • Residents
  • Board Candidates
  • Advanced Practice Providers
  • Physician Assistants

Learning Objectives

After completing this activity, learners will be able to: 

  1. Assess their knowledge of urology
  2. Demonstrate an increased knowledge base of urology
  3. Apply increased knowledge to improve the quality of patient care
  4. Evaluate strengths and weaknesses in urology upon review of their personalized participant profile
  5. Develop a personalized study program to improve their foundation of knowledge 
  6. Discuss core knowledge of urology necessary for the ABU's Qualifying and Recertification Examinations
Course summary
Course opens: 
Course expires: 

ABU/AUA Examination Committee Credentials and Disclosures

Christopher L. Amling, MD John Barry Professor and Chair, Department of Urology, Oregon Health & Science University. AbbVie Pharmaceuticals (Consultant/Advisor).

Mark P. Cain, MD Professor of Urology, Department of Urology, Indiana University School of Medicine, Chief of Pediatric Urology, Riley Hospital for Children at IU Health. No Disclosures.

Anthony A. Caldamone, MD Professor of Surgery (Urology) and Pediatrics, The Warren Alpert School of Medicine of Brown University, Urology Residency Program Director, Head Section of Pediatric Urology, Hasbro Children’s Hospital. No Disclosures.

Sam S. Chang, MD, MBA Patricia and Rodes Hart Endowed Chair in Urologic Surgery, Professor of Urologic Surgery and Oncology, Vanderbilt University Medical Center. Astellas, GLG, Janssen (Consultant/Advisor); NIH (Scientific Study/Trial).

Peter E. Clark, MD Professor of Urologic Surgery, Residency Program Director, Vanderbilt University Medical Center. Galil Medical, Genentech (Consultant/Advisor).

J. Quentin Clemens, MD Professor of Urology, Director, Division of Neurourology and Pelvic Reconstructive Surgery, The University of Michigan Medical Center. No Disclosures.

Donna M. Connelly, BS Program Coordinator. No Disclosures.

Christopher S. Cooper, MD Professor and Vice Chairman of Urology, Director of Pediatric Urology, Senior Associate Dean for Medical Education, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, University of Iowa Hospitals and Clinics. No Disclosures.

Raymond A. Costabile, MD Jay Y. Gillenwater Professor of Urology and Chairman of Urology Department, University of Virginia. Lilly/Icos (Consultant/Advisor, Scientific Study/Trial); Vivus (Scientific Study/Trial).

Sean P. Elliott, MD, MS Professor and Vice Chairman, of the Department of Urology and Director of Reconstructive Urology, University of Minnesota. American Medical Systems (Consultant/Advisor, Meeting Participant/Lecturer); GT Urological, Urotronic (Consultant/Advisor); Percuvision (Leadership Position/Investment Interest).

Alexander Gomelsky, MD Professor and Interim Chair, Director of Female Urology, Neurourology, and Reconstructive Pelvic Surgery, Department of Urology, Louisiana State University Health - Shreveport. No Disclosures.

CD Anthony Herndon, MD, FAAP Professor of Surgery (Urology), Chief Pediatric Urology, Virginia Commonwealth University, Co-Surgeon-in-Chief, Children’s Hospital of Richmond. No Disclosures.

Douglas A. Husmann, MD Anson L Clark, Professor of Urology, Department of Urology, Mayo Clinic, Rochester, MN. No Disclosures.

Andrew T. Jones, PhD Psychometrician, American Board of Surgery. No Disclosures.

Mohit Khera, MD, MBA, MPH Associate Professor of Urology, Division of Male Reproductive Medicine and Surgery, Baylor College of Medicine. Coloplast (Consultant/Advisor, Meeting Participant/Lecturer); Allergan (Scientific Study/Trial); Endo Pharmaceuticals, Abbvie, Lipocine, Repros (Consultant/Advisor); Sprout Pharmaceuticals (Investment Interest); Journal of Sexual Medicine (Health Publishing); Sexual Medicine Society of North American (Leadership Position); Boston Scientific (Consultant/Advisor, Scientific Study/Trial).

Jason P. Kopp, PhD Psychometrician, American Board of Surgery. No Disclosures.

Gary E. Lemack, MD Professor of Urology and Neurology, Rose Mary Haggar Professor Residency Program Director in Urology, Program Director, Female Pelvic Medicine and Reconstructive Surgery, Department of Urology, University of Texas Southwestern Medical Center. Astellas, Allergan (Meeting Participant/Lecturer, Consultant/Advisor); Medtronic (Consultant/Advisor).

Daniel W. Lin, MD Professor and Chief of Urologic Oncology, Department of Urology, Bridges Endowed Professorship in Prostate Cancer Research, University of Washington. Astellas, Bayer (Consultant/Advisor); Myriad (Consultant/Advisor, Meeting Participant/Lecturer); GenProbe, NIH/NCI, Department of Defense, Veteran’s Affairs, Genomic Health, GenomeDx (Scientific Study/Trial).

Brian R. Matlaga, MD, MPH Professor of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine. Boston Scientific (Consultant/Advisor).

Ajay K. Nangia, MD, MBBS Professor of Urology, Director of Andrology: Male Infertility, Microsurgery, Men's Health, Dept of Urology, University of Kansas Hospital and Medical Center. No Disclosures.

Victor Nitti, MD Chair, AUA Office of Education, Professor and Vice Chair, Department of Urology, Professor, Department of Obstetrics and Gynecology, Director, Female Pelvic Medicine and Reconstructive Surgery Program, Female Pelvic Medicine Fellowship Program, New York University School of Medicine. Cook Myosite (Scientific Study/Trial); Serenity Pharmaceuticals (Investment Interest); Astellas, Allergan (Health Publishing, Scientific Study/Trial).

Minhe Oum, BA Education Coordinator, AUA Office of Education. No Disclosures.

John D. Seigne, MD Associate Professor of Urology, Chief Section of Urology, Geisel School of Medicine, Dartmouth. Johnson & Johnson (Investment Interest).

Raj S. Pruthi, MD Professor, Chair, Department of Urology, The University of North Carolina at Chapel Hill. Photocure (Consultant/Advisor).

Li-Ming Su, MD David A. Cofrin Professor and Chairman, Department of Urology, University of Florida College of Medicine. Titan Medical, (Consultant/Advisor); Springer – Atlas of Robotic Urologic Surgery (Health Publishing).

Sandip P. Vasavada, MD Urologic Director, Center for Female Pelvic Medicine and Reconstructive Surgery, Professor of Surgery (Urology), Cleveland Clinic Lerner College of Medicine, Glickman Urological Institute, Cleveland Clinic. Medtronic (Meeting Participant/Lecturer); NDI Medical LLC (Investment Interest); Allergan (Consultant/Advisor, Meeting Participant/Lecturer, Scientific Study/Trial); Axonics, (Consultant/Advisor).

John S. Wiener, MD Head of Section of Pediatric Urology, Professor of Urologic Surgery and Pediatrics, Duke University Medical Center. No Disclosures.

CME Credits Expiration

Please note: CME Credits expire after three years of original release date. Answers must be submitted by the CME credits expiration deadline to receive credit for that year. Refer to CME expiration table below:

 CME Credits Expiration Date
2019 SASPDecember 31, 2021
2018 SASPDecember 31, 2020
2017 SASPDecember 31, 2019
2016 and prior yearsNot eligible for CME credits.

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement: The American Urological Association designates this enduring material for a maximum of 20.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Original Release Date: January 2017 Expiration Date: December 2019

AAPA Credit Designation Statement: This Self-Assessment CME program has been reviewed and is approved for a maximum of 20.00 AAPA Category 1 Self-Assessment CME credits by the Physician Assistant Review Panel. Approval is valid one year from the release date of January 1, 2017. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity. This program was planned in accordance with AAPA’s CME Standards.

Original Release Date: January 2017 Expiration Date: December 2017

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Estimated time for study, test completion, and reference reading for each SASP is 20 hours.

Target Audience: This self-assessment program is designed for practicing urologists, Board candidates, residents and/or physician assistants.

Purpose/Need: Urologists and other health care providers need to assess their knowledge of urology. Identified gaps in this knowledge can lead to individualized, practical educational activities, which will result in improved patient care.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: The material contained in this examination is protected under U.S. Copyright law. Duplication of any part of this examination by any means including, but not limited to, photographic reproduction is a FEDERAL OFFENSE.

Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.


Please login or register to take this course.